1. Home
  2. GRDN vs IMCR Comparison

GRDN vs IMCR Comparison

Compare GRDN & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardian Pharmacy Services Inc.

GRDN

Guardian Pharmacy Services Inc.

HOLD

Current Price

$34.39

Market Cap

2.1B

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$30.09

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRDN
IMCR
Founded
2004
2008
Country
United States
United Kingdom
Employees
3400
N/A
Industry
Retail-Drug Stores and Proprietary Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
GRDN
IMCR
Price
$34.39
$30.09
Analyst Decision
Strong Buy
Buy
Analyst Count
3
12
Target Price
$37.33
$61.82
AVG Volume (30 Days)
246.1K
358.8K
Earning Date
03-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.39
EPS
N/A
N/A
Revenue
N/A
$249,428,000.00
Revenue This Year
$1.13
$14.39
Revenue Next Year
$9.97
$8.19
P/E Ratio
$117.77
N/A
Revenue Growth
N/A
43.05
52 Week Low
$19.17
$23.15
52 Week High
$37.43
$40.71

Technical Indicators

Market Signals
Indicator
GRDN
IMCR
Relative Strength Index (RSI) 57.90 37.46
Support Level $27.73 N/A
Resistance Level $36.13 $34.86
Average True Range (ATR) 1.91 1.42
MACD 0.01 -0.24
Stochastic Oscillator 67.25 10.17

Price Performance

Historical Comparison
GRDN
IMCR

About GRDN Guardian Pharmacy Services Inc.

Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: